{"nctId":"NCT02914275","briefTitle":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.","startDateStruct":{"date":"2016-09-27","type":"ACTUAL"},"conditions":["Influenza, Human"],"count":2250,"armGroups":[{"label":"Seqirus QIV Cohort A","type":"EXPERIMENTAL","interventionNames":["Biological: Seqirus Quadrivalent Inactivated Influenza Vaccine"]},{"label":"Seqirus QIV Cohort B","type":"EXPERIMENTAL","interventionNames":["Biological: Seqirus Quadrivalent Inactivated Influenza Vaccine"]},{"label":"Comparator QIV Cohort A","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator Quadrivalent Inactivated Influenza Vaccine"]},{"label":"Comparator QIV Cohort B","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator Quadrivalent Inactivated Influenza Vaccine"]}],"interventions":[{"name":"Seqirus Quadrivalent Inactivated Influenza Vaccine","otherNames":["Seqirus QIV"]},{"name":"Comparator Quadrivalent Inactivated Influenza Vaccine","otherNames":["Comparator QIV"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subject 6 months through to 59 months of age at the time of first vaccination and born between 36 and 42 weeks of gestation;\n* Parent or legally acceptable representative able to provide written informed consent and be willing and able to adhere to all protocol requirements including blood draws.\n* Subject is in generally good health as per the Investigator's medical judgment\n\nExclusion Criteria:\n\n* History of allergic reactions to egg proteins or any components of the Study Vaccines;\n* History of serious adverse reactions to any influenza vaccines;\n* History of Guillain-Barré syndrome or other demyelinating disease such as encephalomyelitis and transverse myelitis;\n* History of licensed or investigational influenza vaccination in the last 6 months;\n* Clinical signs of active infection and/or an axillary temperature of ≥ 99.5°F / (≥ 37.5 °C) on the day of vaccination or within 48 hours preceding vaccination.\n* Current or recent, acute or chronic medical conditions that in the opinion of the Investigator are clinically significant and/or unstable\n* History of any seizures, with the exception of a single febrile seizure;\n* Self-reported or known seropositivity suggestive of acute or chronic viral infection for human immunodeficiency virus, hepatitis B or hepatitis C;\n* Known or suspected congenital or acquired immunosuppressive conditions;\n* Current or recent immunosuppressive or immunomodulatory therapy\n* Current or medical history of malignant neoplasms;\n* Administration of immunoglobulin and/or any blood products within the previous 90 days preceding the administration of the Study Vaccine or planned administration during the study;\n* Participation in a clinical trial or use of an investigational compound within 28 days prior to or 28 days after receiving the Study Vaccine, or plans to enter a study during this period;\n* Vaccination with a licensed vaccine 21 days (for live or inactivated vaccines) prior to receiving the Study Vaccine, or plans to receive any licensed vaccine prior to the Study Exit Visit.\n* Medical conditions or treatment contraindicating intramuscular vaccination due to increased risk of bleeding.\n* Family members of the employees of the Investigator or study center with direct involvement in the study, or with other clinical studies under the direction of that Investigator or study center.","healthyVolunteers":true,"sex":"ALL","minimumAge":"6 Months","maximumAge":"59 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Geometric Mean Titer (GMT) Ratio of Each Virus Strain.","description":"Noninferiority of Seqirus QIV compared to comparator QIV was assessed by hemagglutination inhibition (HI) antibody geometric mean titer (GMT) for each viral strain included in the vaccines. The GMT ratio is defined as the geometric mean of the postvaccination HI titer for the US-licensed comparator QIV over the geometric mean of the postvaccination HI titer for Seqirus QIV.\n\nB/VIC = B/Victoria B/YAM = B/Yamagata","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"370.0","spread":null},{"groupId":"OG001","value":"311.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"436.8","spread":null},{"groupId":"OG001","value":"589.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":null},{"groupId":"OG001","value":"29.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"57.9","spread":null}]}]}]},{"type":"PRIMARY","title":"The Difference in Seroconversion Rate (SCR) for Each Virus Strain.","description":"Noninferiority of Seqirus QIV compared to comparator QIV will be assessed by seroconversion rate (SCR) for each viral strain. SCR is defined as the percentage of subjects with either a prevaccination HI titer \\< 1:10 and a postvaccination HI titer ≥ 1:40, or a prevaccination HI titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination HI titer. For the SCR comparison, the difference between the SCR for each vaccine (for each strain) will be determined.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.1","spread":null},{"groupId":"OG001","value":"68.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":null},{"groupId":"OG001","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.9","spread":null},{"groupId":"OG001","value":"41.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"61.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Solicited Local Adverse Reactions and Solicited Systemic Adverse Events (AE)","description":"Frequency and severity of solicited local adverse reactions and systemic AEs for 7 days after each vaccination dose","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"940","spread":null},{"groupId":"OG001","value":"312","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"592","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"645","spread":null},{"groupId":"OG001","value":"208","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"633","spread":null},{"groupId":"OG001","value":"215","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Cellulitis-like Reactions","description":"Frequency of cellulitis-like reactions for at least 28 days after each vaccination dose","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Unsolicited AEs","description":"Frequency and severity of unsolicited AEs for at least 28 days after each vaccination dose","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"536","spread":null},{"groupId":"OG001","value":"171","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"285","spread":null},{"groupId":"OG001","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"206","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Serious Adverse Events (SAE)","description":"Frequency of SAEs for 180 days after the last vaccination dose. SAE = serious adverse events, AESI = adverse event of special interest","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean of Hemagglutination Titers (HI GMTs) Prevaccination (Day 1) and Postvaccination (Study Exit Visit) of Each Virus Strain","description":"The humoral immune response will be assessed for Seqirus QIV \\& comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate geometric mean of HI titers prevaccination \\& postvaccination.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.8","spread":null},{"groupId":"OG001","value":"60.7","spread":null},{"groupId":"OG002","value":"14.9","spread":null},{"groupId":"OG003","value":"68.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184.9","spread":null},{"groupId":"OG001","value":"590.2","spread":null},{"groupId":"OG002","value":"168.3","spread":null},{"groupId":"OG003","value":"469.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.3","spread":null},{"groupId":"OG001","value":"62.4","spread":null},{"groupId":"OG002","value":"16.4","spread":null},{"groupId":"OG003","value":"65.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184.9","spread":null},{"groupId":"OG001","value":"778.6","spread":null},{"groupId":"OG002","value":"247.5","spread":null},{"groupId":"OG003","value":"1047","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"7.9","spread":null},{"groupId":"OG002","value":"5.8","spread":null},{"groupId":"OG003","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6","spread":null},{"groupId":"OG001","value":"35.4","spread":null},{"groupId":"OG002","value":"16.3","spread":null},{"groupId":"OG003","value":"44.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"9.6","spread":null},{"groupId":"OG002","value":"6.9","spread":null},{"groupId":"OG003","value":"10.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.8","spread":null},{"groupId":"OG001","value":"72.1","spread":null},{"groupId":"OG002","value":"31.9","spread":null},{"groupId":"OG003","value":"85.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rates (SCRs) of Each Virus Strain","description":"The humoral immune response will be assessed for Seqirus QIV \\& comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate SCRs defined as the % of subjects with either a prevaccination HI titer \\< 1:10 and a postvaccination HI titer ≥ 1:40 or a prevaccination titer ≥ 1:10 and a ≥ 4-fold increase in postvaccination titer.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null},{"groupId":"OG001","value":"77.1","spread":null},{"groupId":"OG002","value":"80.3","spread":null},{"groupId":"OG003","value":"61.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.4","spread":null},{"groupId":"OG001","value":"82.2","spread":null},{"groupId":"OG002","value":"85.0","spread":null},{"groupId":"OG003","value":"84.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":null},{"groupId":"OG001","value":"49.9","spread":null},{"groupId":"OG002","value":"26.9","spread":null},{"groupId":"OG003","value":"51.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.9","spread":null},{"groupId":"OG001","value":"65.1","spread":null},{"groupId":"OG002","value":"49.7","spread":null},{"groupId":"OG003","value":"68.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroprotection Rates of Each Virus Strain","description":"The humoral immune response will be assessed for Seqirus QIV \\& comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate the percentage of subjects with a titer ≥40 (seroprotection rates) at Day 1 and at Study Exit Visit.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.1","spread":null},{"groupId":"OG001","value":"99.1","spread":null},{"groupId":"OG002","value":"88.6","spread":null},{"groupId":"OG003","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.5","spread":null},{"groupId":"OG001","value":"98.4","spread":null},{"groupId":"OG002","value":"95.3","spread":null},{"groupId":"OG003","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":null},{"groupId":"OG001","value":"57.1","spread":null},{"groupId":"OG002","value":"29.0","spread":null},{"groupId":"OG003","value":"61.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.6","spread":null},{"groupId":"OG001","value":"71.0","spread":null},{"groupId":"OG002","value":"52.8","spread":null},{"groupId":"OG003","value":"75.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Increase (GMFI) of Each Virus Strain","description":"The humoral immune response will be assessed for Seqirus QIV \\& comparator QIV. Serum HI titers against the 4 influenza vaccine strains will be used to calculate GMFIs, defined as the geometric mean fold titer change (rise) from Day 1 to Study Exit Visit.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.4","spread":null},{"groupId":"OG001","value":"9.7","spread":null},{"groupId":"OG002","value":"11.3","spread":null},{"groupId":"OG003","value":"6.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"12.5","spread":null},{"groupId":"OG002","value":"15.1","spread":null},{"groupId":"OG003","value":"16.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"2.8","spread":null},{"groupId":"OG003","value":"5.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":null},{"groupId":"OG001","value":"7.5","spread":null},{"groupId":"OG002","value":"4.6","spread":null},{"groupId":"OG003","value":"8.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":1673},"commonTop":["Cough","Rhinorrhoea","Pyrexia","Upper respiratory tract infection"]}}}